Senior Management Team

Senior Management Team

John Sedor

Chairman and Chief Executive Officer

READ BIOGRAPHY

John Sedor has served as our Chairman and Chief Executive Officer since July 2018. Mr. Sedor has been Chairman of the Board and Chief Executive Officer of Pernix Therapeutics since July 2016 and Chairman and Chief Executive Officer of SEDOR Pharmaceuticals, LLC since 2014. Mr. Sedor served as President, Chief Executive Officer and a director of Cangene Corporation, a fully integrated developer and manufacturer of immune therapeutics, from 2011 until its acquisition by Emergent Biosolutions in February 2014. Prior to that, from 2008 until 2011, Mr. Sedor served as President and Chief Executive Officer of CPEX Pharmaceuticals, or CPEX, after its 2008 spin-off from Bentley Pharmaceuticals, Inc., or Bentley, and until its 2011 acquisition by Footstar, Inc. Mr. Sedor was President of Bentley from 2005 until the spin-off of CPEX. From 2001 to May 2005, he was President and CEO of Sandoz, Inc. (a division of Novartis AG). From 1998-2001 Mr. Sedor was President and Chief Executive Officer at Verion, Inc., a drug delivery company. Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.

CLOSE

Kenneth R. Piña

Executive Vice President

READ BIOGRAPHY

Ken Piña has served as our Executive Vice President since July 2018. Mr. Piña has been the Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary of Pernix Therapeutics since January 2017. Most recently, Mr. Piña was a Founder and the Managing Principal of Core Risks Ltd. (CRL), a global compliance and risk management consultancy firm that was acquired by Jardine Lloyd Thompson. He formerly served as the Senior Vice President, Chief Legal Officer and Secretary for Henkel Corporation. Before joining Henkel, Mr. Piña served as Vice President, General Counsel and Secretary of Rhone-Poulenc Rorer Pharmaceuticals Inc. Mr. Piña received his Juris Doctorate from the Dickinson School of Law, Pennsylvania State University, and earned his B.S. degree from the Rutgers University College of Pharmacy. He has served as an adjunct professor of food and drug law at Temple University and as a lecturer in law at the Villanova School of Law. He is also co-editor of the industry text, An Introduction to Food and Drug Law and Regulation (FDLI), now in its fifth edition.

CLOSE

Monica Forbes

Vice President, Chief Financial Officer

READ BIOGRAPHY

Monica Forbes joined Orexigen in 2014 and is currently Vice President and Chief Financial Officer. Over the last 3.5 years, Monica has made tremendous contributions to the organization, guiding the development and oversight of the company’s budget process, supporting the financial planning and analysis for the U.S. business and working with the executive team on our strategic outreach process. Monica has over 15 years of financial planning & analysis experience in the biopharmaceutical and telecommunications industries. She joined Orexigen from Amylin where she served as an Associate Director, Financial Business Partner leading financial planning and reporting activities for a $300M division. Prior to that, Monica held a variety of finance roles at Invitrogen, Ericsson and Qualcomm. Monica holds a B.S. in Business Administration with an emphasis in accounting from San Diego State University.

CLOSE

Amy Halseth

Vice President, Clinical Development

READ BIOGRAPHY

Amy Halseth joined Orexigen in 2012 where she served as the Vice President of Clinical Development and Medical Affairs.  At Nalpropion Pharmaceuticals, Amy will oversee the Global Development, Regulatory, and Pharmacovigilance functions. Amy has over 20 years of experience in the biopharmaceutical industry, having worked in preclinical research, clinical development, and medical affairs roles, and has contributed to regulatory strategy leading to product approvals in the US, Europe, and Canada. Prior to her role at Nalpropion, Amy held positions at Roche/Genentech, Amylin Pharmaceuticals, and Pharmacia, with a focus on obesity and other metabolic diseases. Amy holds a Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University.

CLOSE

Kris Hanson

Vice President, Legal & Compliance

READ BIOGRAPHY

Kris Hanson joined Orexigen Therapeutics in 2016 and currently serves as Vice President, Legal & Compliance for Nalpropion Pharmaceuticals.  Kris has more than 20 years of experience advising public and private companies across multiple industries with respect to corporate governance, capital markets and strategic transactions, commercial contracting and licensing, IP portfolio management, compliance and litigation.  Prior to his roles at Nalpropion and Orexigen, Kris served in progressively senior legal roles at SAIC, Cricket Communications, and Lytx.  Before beginning his in-house career, Kris was in private practice as a corporate lawyer at Morrison & Foerster LLP and Brobeck, Phleger & Harrison LLP, after having served as a judicial law clerk for U.S. District Court Judge John S. Rhoades.  Kris received a B.A. from Georgetown University and a J.D. from the UCLA School of Law.

CLOSE